Mirum Pharmaceuticals Inc
NASDAQ:MIRM

Watchlist Manager
Mirum Pharmaceuticals Inc Logo
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Watchlist
Price: 102.51 USD -0.4% Market Closed
Market Cap: $5.3B

Net Margin

-8.8%
Current
Improving
by 64.4%
vs 3-y average of -73.2%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-8.8%
=
Net Income
$-41.6m
/
Revenue
$471.8m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-8.8%
=
Net Income
$-41.6m
/
Revenue
$471.8m

Peer Comparison

Country Company Market Cap Net
Margin
US
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
5.3B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
395.2B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.2B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175.6B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.8B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.3B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
31th
Based on 15 072 companies
31th percentile
-8.8%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Mirum Pharmaceuticals Inc
Glance View

Market Cap
5.3B USD
Industry
Biotechnology

In the competitive landscape of the biopharmaceutical industry, Mirum Pharmaceuticals Inc. has carved a niche for itself by specializing in rare liver diseases, a domain that requires both precision and dedication. Founded with a visionary goal, the company primarily focuses on developing treatments that address serious unmet needs within this sphere. At the heart of its operations is the development of maralixibat, a promising drug targeting progressive familial intrahepatic cholestasis and Alagille syndrome, which are both debilitating liver conditions affecting young patients. By addressing these niche markets, Mirum positions itself uniquely, translating complex science into tangible health outcomes. The company makes its money by navigating the rigorous path of drug development, from clinical trials to receiving regulatory approvals, ultimately transforming these therapies into marketable products. Mirum's business model is interlaced with the high stakes world of pharmaceuticals, where innovation meets exhaustive research and development. Revenue generation is contingent upon both the successful commercialization of its drug pipeline and strategic partnerships, which bolster their market reach and resource agility. By engaging closely with healthcare professionals and leveraging compassionate use and expanded access programs, they not only facilitate early adoption but also fuel the momentum needed for market penetration. Moreover, Mirum's commitment to education and engagement strategies fosters a robust ecosystem that underscores the importance of treating rare diseases. This way, the company not only sells its therapeutics but also creates enduring relationships within the medical community, significantly anchoring its financial and operational standing.

MIRM Intrinsic Value
41.2 USD
Overvaluation 60%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-8.8%
=
Net Income
$-41.6m
/
Revenue
$471.8m
What is Mirum Pharmaceuticals Inc's current Net Margin?

The current Net Margin for Mirum Pharmaceuticals Inc is -8.8%, which is above its 3-year median of -73.2%.

How has Net Margin changed over time?

Over the last 3 years, Mirum Pharmaceuticals Inc’s Net Margin has increased from -79.7% to -8.8%. During this period, it reached a low of -176.1% on Dec 31, 2022 and a high of -8.8% on Sep 30, 2025.

Back to Top